These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Optimal management of the T1G3 bladder cancer. Manoharan M; Soloway MS Urol Clin North Am; 2005 May; 32(2):133-45. PubMed ID: 15862611 [TBL] [Abstract][Full Text] [Related]
26. Optimal timing of radical cystectomy for patients with T1 bladder cancer. Bochner BH Urol Oncol; 2009; 27(3):329-31. PubMed ID: 19414124 [TBL] [Abstract][Full Text] [Related]
27. When intravesical measures fail. Indications for cystectomy in superficial disease. Hudson MA Urol Clin North Am; 1992 Aug; 19(3):601-9. PubMed ID: 1636242 [TBL] [Abstract][Full Text] [Related]
28. The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder. Cho KS; Seo JW; Park SJ; Lee YH; Choi YD; Cho NH; Yang SC; Hong SJ Urol Int; 2009; 82(3):306-11. PubMed ID: 19440019 [TBL] [Abstract][Full Text] [Related]
30. De novo muscle invasive bladder cancer: is there a change in trend? Vaidya A; Soloway MS; Hawke C; Tiguert R; Civantos F J Urol; 2001 Jan; 165(1):47-50; discussion 50. PubMed ID: 11125361 [TBL] [Abstract][Full Text] [Related]
31. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. Kassouf W; Swanson D; Kamat AM; Leibovici D; Siefker-Radtke A; Munsell MF; Grossman HB; Dinney CP J Urol; 2006 Jun; 175(6):2058-62. PubMed ID: 16697803 [TBL] [Abstract][Full Text] [Related]
32. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. Karakiewicz PI; Shariat SF; Palapattu GS; Gilad AE; Lotan Y; Rogers CG; Vazina A; Gupta A; Bastian PJ; Perrotte P; Sagalowsky AI; Schoenberg M; Lerner SP J Urol; 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2. PubMed ID: 16952631 [TBL] [Abstract][Full Text] [Related]
33. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. Holzbeierlein JM; Lopez-Corona E; Bochner BH; Herr HW; Donat SM; Russo P; Dalbagni G; Sogani PC J Urol; 2004 Sep; 172(3):878-81. PubMed ID: 15310988 [TBL] [Abstract][Full Text] [Related]
35. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. Dutta SC; Smith JA; Shappell SB; Coffey CS; Chang SS; Cookson MS J Urol; 2001 Aug; 166(2):490-3. PubMed ID: 11458053 [TBL] [Abstract][Full Text] [Related]
36. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin. Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815 [TBL] [Abstract][Full Text] [Related]
37. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis. Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663 [TBL] [Abstract][Full Text] [Related]
38. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743 [TBL] [Abstract][Full Text] [Related]